While inhibitory studies against FAK, mTOR, and Akt components in meningioma patients are ongoing (38); our study provides mechanistic insights on how components of Cytoskeletal regulators, PI3K-Akt, mTOR, and NFκB can be targeted using a single molecule namely the Cpd22 which was able to downplay these components in meningioma primaries. Here, PTK2 is linked to meningioma.